BACKGROUND: Spine stereotactic body radiotherapy (SBRT) is increasingly being applied to the postoperative spine metastases patient. Our aim was to identify clinical and dosimetric predictors of local control (LC) and survival. METHODS: Eighty patients treated between October 2008 and February 2012 with postoperative SBRT were identified from our prospective database and retrospectively reviewed. RESULTS: The median follow-up was 8.3 months. Thirty-five patients (44%) were treated with 18-26 Gy in 1 or 2 fractions, and 45 patients (56%) with 18-40 Gy in 3-5 fractions. Twenty-one local failures (26%) were observed, and the 1-year LC and overall survival (OS) rates were 84% and 64%, respectively. The most common site of failure was within the epidural space (15/21, 71%). Multivariate proportional hazards analysis identified systemic therapy post-SBRT as the only significant predictor of OS (P = .02) and treatment with 18-26 Gy/1 or 2 fractions (P = .02) and a postoperative epidural disease grade of 0 or 1 (0, no epidural disease; 1, epidural disease that compresses dura only, P = .003) as significant predictors of LC. Subset analysis for only those patients (n = 48/80) with high-grade preoperative epidural disease (cord deformed) indicated significantly greater LC rates when surgically downgraded to 0/1 vs 2 (P = .0009). CONCLUSIONS: Postoperative SBRT with high total doses ranging from 18 to 26 Gy delivered in 1-2 fractions predicted superior LC, as did postoperative epidural grade.
BACKGROUND: Spine stereotactic body radiotherapy (SBRT) is increasingly being applied to the postoperative spine metastasespatient. Our aim was to identify clinical and dosimetric predictors of local control (LC) and survival. METHODS: Eighty patients treated between October 2008 and February 2012 with postoperative SBRT were identified from our prospective database and retrospectively reviewed. RESULTS: The median follow-up was 8.3 months. Thirty-five patients (44%) were treated with 18-26 Gy in 1 or 2 fractions, and 45 patients (56%) with 18-40 Gy in 3-5 fractions. Twenty-one local failures (26%) were observed, and the 1-year LC and overall survival (OS) rates were 84% and 64%, respectively. The most common site of failure was within the epidural space (15/21, 71%). Multivariate proportional hazards analysis identified systemic therapy post-SBRT as the only significant predictor of OS (P = .02) and treatment with 18-26 Gy/1 or 2 fractions (P = .02) and a postoperative epidural disease grade of 0 or 1 (0, no epidural disease; 1, epidural disease that compresses dura only, P = .003) as significant predictors of LC. Subset analysis for only those patients (n = 48/80) with high-grade preoperative epidural disease (cord deformed) indicated significantly greater LC rates when surgically downgraded to 0/1 vs 2 (P = .0009). CONCLUSIONS: Postoperative SBRT with high total doses ranging from 18 to 26 Gy delivered in 1-2 fractions predicted superior LC, as did postoperative epidural grade.
Authors: Dirk Rades; Stefan Huttenlocher; Amira Bajrovic; Johann H Karstens; Irenaeus A Adamietz; Nadja Kazic; Volker Rudat; Steven E Schild Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-27 Impact factor: 7.038
Authors: Steven C Kirshblum; Stephen P Burns; Fin Biering-Sorensen; William Donovan; Daniel E Graves; Amitabh Jha; Mark Johansen; Linda Jones; Andrei Krassioukov; M J Mulcahey; Mary Schmidt-Read; William Waring Journal: J Spinal Cord Med Date: 2011-11 Impact factor: 1.985
Authors: A Sahgal; D Roberge; D Schellenberg; T G Purdie; A Swaminath; J Pantarotto; E Filion; Z Gabos; J Butler; D Letourneau; G L Masucci; L Mulroy; A Bezjak; L A Dawson; M Parliament Journal: Clin Oncol (R Coll Radiol) Date: 2012-05-24 Impact factor: 4.126
Authors: Mark H Bilsky; Ilya Laufer; Daryl R Fourney; Michael Groff; Meic H Schmidt; Peter Paul Varga; Frank D Vrionis; Yoshiya Yamada; Peter C Gerszten; Timothy R Kuklo Journal: J Neurosurg Spine Date: 2010-09
Authors: Arjun Sahgal; Mark Bilsky; Eric L Chang; Lijun Ma; Yoshiya Yamada; Laurence D Rhines; Daniel Létourneau; Matthew Foote; Eugene Yu; David A Larson; Michael G Fehlings Journal: J Neurosurg Spine Date: 2010-12-24
Authors: Ran Harel; Samuel Chao; Ajit Krishnaney; Todd Emch; Edward C Benzel; Lilyana Angelov Journal: World Neurosurg Date: 2011-01-12 Impact factor: 2.104
Authors: Marcelo V R Cunha; Ameen Al-Omair; Eshetu G Atenafu; Giuseppina Laura Masucci; Daniel Letourneau; Renee Korol; Eugene Yu; Peter Howard; Fiona Lochray; Leodante B da Costa; Michael G Fehlings; Arjun Sahgal Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-01 Impact factor: 7.038
Authors: Arjun Sahgal; Lijun Ma; Vivian Weinberg; Iris C Gibbs; Sam Chao; Ung-Kyu Chang; Maria Werner-Wasik; Liliyanna Angelov; Eric L Chang; Moon-Jun Sohn; Scott G Soltys; Daniel Létourneau; Sam Ryu; Peter C Gerszten; Jack Fowler; C Shun Wong; David A Larson Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo Journal: CNS Oncol Date: 2017-07-18
Authors: Ilya Laufer; Simon S Lo; Eric L Chang; Jason Sheehan; Matthias Guckenberger; Moon-Jun Sohn; Samuel Ryu; Matthew Foote; Alexander Muacevic; Scott G Soltys; Samuel Chao; Sten Myrehaug; Peter C Gerszten; Eric Lis; Pejman Maralani; Mark Bilsky; Charles Fisher; Laurence Rhines; Jorrit-Jan Verlaan; David Schiff; Michael G Fehlings; Lijun Ma; Susan Chang; Wendy R Parulekar; Michael A Vogelbaum; Arjun Sahgal Journal: Neuro Oncol Date: 2018-08-02 Impact factor: 12.300
Authors: Rachit Kumar; Anick Nater; Ahmed Hashmi; Sten Myrehaug; Young Lee; Lijun Ma; Kristin Redmond; Simon S Lo; Eric L Chang; Albert Yee; Charles G Fisher; Michael G Fehlings; Arjun Sahgal Journal: Neurooncol Pract Date: 2015-07-27